Why Screen? - The Hepatitis-HCC Link
- Chronic viral hepatitis (HBV & HCV) is the leading driver of Hepatocellular Carcinoma (HCC).
- Mechanism: Persistent inflammation → hepatocyte regeneration → fibrosis → cirrhosis.
- HBV: Directly oncogenic; viral DNA integrates into the host genome, causing HCC even without cirrhosis.
- HCV: Indirectly oncogenic; HCC risk is primarily mediated through chronic inflammation leading to cirrhosis.
- Goal: Early detection via screening improves survival.

⭐ Up to 50% of HBV-related HCC cases occur in patients without cirrhosis, making screening crucial for all chronic carriers, not just those with cirrhosis.
Screening Indications - The Cirrhosis Club
-
All patients with established cirrhosis are candidates for HCC screening, regardless of etiology (HCV, HBV, NAFLD, alcohol).
- Screening consists of an abdominal ultrasound every 6 months.
- Alpha-fetoprotein (AFP) may be used as an adjunct, but has limitations in sensitivity and specificity.
-
Certain high-risk groups with chronic Hepatitis B without cirrhosis also warrant screening:
- Asian males > 40 years old
- Asian females > 50 years old
- Individuals of African descent
- Those with a first-degree relative with HCC
⭐ Achieving a sustained virologic response (SVR) in Hepatitis C reduces HCC risk by ~75%. However, the risk is not eliminated. Patients with pre-existing cirrhosis MUST continue HCC surveillance even after a curative course of direct-acting antivirals (DAAs).
The Screening Playbook - Scan & See
- Primary Tool: Abdominal ultrasound (US) of the liver every 6 months.
- Adjunct Biomarker: Alpha-fetoprotein (AFP).
- A rising trend is more significant than a single value.
- Goal: Detect small, early-stage tumors for curative therapy.

⭐ While AFP has limitations, a value >20 ng/mL should prompt further imaging regardless of ultrasound findings.
Positive Screen? - The Follow-Up Flow
- For patients with cirrhosis or chronic hepatitis B, surveillance with ultrasound (US) is key.

⭐ Classic imaging features of HCC on multiphasic CT/MRI are arterial phase hyperenhancement (APHE) and venous/delayed phase washout. These findings are highly specific (LI-RADS 5) and can establish a diagnosis without biopsy.
High‑Yield Points - ⚡ Biggest Takeaways
- All patients with cirrhosis, regardless of etiology, require HCC screening.
- Patients with chronic hepatitis B may require screening even without cirrhosis.
- The standard screening modality is abdominal ultrasound every 6 months.
- Alpha-fetoprotein (AFP) has low sensitivity and is not recommended for standalone screening.
- The primary goal is early detection of hepatocellular carcinoma to improve outcomes.
- Cirrhosis remains the single most important risk factor for HCC development.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app